1-(2,5-difluorophenyl)-2-aminopropane | 32560-78-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(2,5-difluorophenyl)-2-aminopropane
• 英文别名: 1-(2,5-Difluorophenyl)propan-2-amine
• CAS: 32560-78-4
• 化学式: C₉H₁₁F₂N
• 分子量: 171.19
• InChiKey: CPUFOJBJRNFEBB-UHFFFAOYSA-N

物化性质

• 沸点：
  208.6±25.0 °C(Predicted)
• 密度：
  1.131±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2,5-difluorophenyl)-2-aminopropane 、 三氟乙酸酐 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.25h， 以1.33 g的产率得到N-trifluoroacetyl-1-(2,5-difluorophenyl)-2-aminopropane
  参考文献：
  名称：

  The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands

  摘要：

  The lipophilicity of a set of 5-HT2A ligands was determined using immobilized-artificial-membrane chromatography, a method that generates values well correlated with octanol-water partition coefficients. For agonists, a highly significant linear correlation was observed between binding affinity and lipophilicity. For ligands exhibiting partial agonist or antagonist properties, the lipophilicity was consistently higher than would be expected for an agonist of comparable affinity. The results suggest a possible method for distinguishing agonists from antagonists in high-throughput screening when a direct assay for functional activity is either unavailable or impractical. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.02.033
• 作为产物：
  描述：

  2,5-difluoro-β-methyl-β-nitrovinylbenzene 在 sodium tetrahydroborate 、 三氟化硼乙醚 作用下， 以 四氢呋喃 为溶剂， 反应 5.5h， 生成 1-(2,5-difluorophenyl)-2-aminopropane
  参考文献：
  名称：

  The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands

  摘要：

  The lipophilicity of a set of 5-HT2A ligands was determined using immobilized-artificial-membrane chromatography, a method that generates values well correlated with octanol-water partition coefficients. For agonists, a highly significant linear correlation was observed between binding affinity and lipophilicity. For ligands exhibiting partial agonist or antagonist properties, the lipophilicity was consistently higher than would be expected for an agonist of comparable affinity. The results suggest a possible method for distinguishing agonists from antagonists in high-throughput screening when a direct assay for functional activity is either unavailable or impractical. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.02.033

文献信息

• TYROSINE KINASE INHIBITORS
  申请人：GREGOR Vlad Edward

  公开号：US20120065233A1

  公开（公告）日：2012-03-15

  The present disclosure relates to the field of tyrosine kinase enzyme inhibition, in particular anaplastic lymphoma kinase (ALK) inhibition using novel small molecules. Provided are compounds capable to modulate ALK activity, compositions that comprise the compounds, and methods of using the compounds for the treatment or prevention of diseases or conditions that are characterized by ALK activity or expression.

  本公开涉及酪氨酸激酶酶抑制领域，特别是使用新型小分子抑制间变性淋巴瘤激酶（ALK）的抑制。提供了能够调节ALK活性的化合物、包含这些化合物的组合物以及使用这些化合物治疗或预防由ALK活性或表达特征的疾病或病症的方法。
• Tyrosine kinase inhibitors
  申请人：Levy Nelson

  公开号：US08822500B2

  公开（公告）日：2014-09-02

  The present disclosure relates to the field of tyrosine kinase enzyme inhibition, in particular anaplastic lymphoma kinase (ALK) inhibition using novel small molecules. Provided are compounds capable to modulate ALK activity, compositions that comprise the compounds, and methods of using the compounds for the treatment or prevention of diseases or conditions that are characterized by ALK activity or expression.

  本公开涉及酪氨酸激酶酶抑制领域，特别是使用新型小分子抑制间变性淋巴瘤激酶（ALK）。提供了能够调节ALK活性的化合物、包含这些化合物的组合物以及使用这些化合物治疗或预防由ALK活性或表达特征的疾病或状况的方法。
• MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS
  申请人：Seattle Genetics, Inc.

  公开号：US20130123465A1

  公开（公告）日：2013-05-16

  Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.

  提供了MeVal-Val-Dil-Dap-Phe（MMAF）的Auristatin肽类类似物，其具有C-末端苯丙氨酸残基侧链替换或修饰，可单独提供或通过各种连接剂连接到配体上。相关的结合物可以定向特定的细胞类型，以提供治疗效益。
• Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus
  申请人：Seattle Genetics, Inc.

  公开号：US10000555B2

  公开（公告）日：2018-06-19

  Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.

  提供的 MeVal-Val-Dil-Dap-Phe (MMAF) Auristatin 肽类似物具有 C 端苯丙氨酸残基侧链替换或修饰，可单独提供或通过各种连接体连接到配体上。相关共轭物可靶向特定细胞类型，提供治疗效果。
• FLUORSUBSTITUIERTE AMPHETAMINE UND AMPHETAMINDERIVATE UND DEREN VERWENDUNG
  申请人：Universität Tübingen

  公开号：EP2121571A1

  公开（公告）日：2009-11-25